Kronos Bio (NASDAQ:KRON - Get Free Report) was downgraded by Piper Sandler from an "overweight" rating to a "neutral" rating in a research report issued on Thursday, Marketbeat.com reports. They presently have a $1.00 price target on the stock, down from their previous price target of $6.00. Piper Sandler's price target would suggest a potential upside of 17.29% from the company's current price.
KRON has been the subject of a number of other reports. TD Cowen cut shares of Kronos Bio from a "buy" rating to a "hold" rating in a research note on Thursday. HC Wainwright reissued a "buy" rating and set a $2.25 target price on shares of Kronos Bio in a research note on Monday, August 19th.
Read Our Latest Stock Analysis on KRON
Kronos Bio Trading Down 3.1 %
Shares of NASDAQ:KRON traded down $0.03 during mid-day trading on Thursday, reaching $0.85. The stock had a trading volume of 478,167 shares, compared to its average volume of 266,102. The company has a market cap of $51.40 million, a P/E ratio of -0.51 and a beta of 1.86. Kronos Bio has a 1 year low of $0.69 and a 1 year high of $1.60. The business's 50 day moving average price is $0.95 and its 200 day moving average price is $1.03.
Institutional Trading of Kronos Bio
Institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Kronos Bio in the first quarter worth about $71,000. Forefront Analytics LLC increased its holdings in Kronos Bio by 75.0% in the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company's stock worth $167,000 after buying an additional 57,867 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Kronos Bio by 17.2% in the 1st quarter. Acadian Asset Management LLC now owns 774,559 shares of the company's stock valued at $1,005,000 after acquiring an additional 113,618 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Kronos Bio by 14.6% in the 1st quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company's stock valued at $2,533,000 after buying an additional 247,918 shares during the period. Institutional investors and hedge funds own 64.09% of the company's stock.
Kronos Bio Company Profile
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Read More
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
